Herein, we have developed a label-free and homogeneous fluorescence resonance energy transfer (FRET) immunoassay for the detection of neopterin (NPT), which is an early and valuable biochemical marker of cellular immunity. Owing to intrinsic fluorescence properties of antibody and NPT, anti-NPT antibody (anti-NPT) and analyte played roles as the respective donor and acceptor in the FRET immunoassay. As the concentration of NPT increases, the fluorescence intensity at ~350 nm decreases owing to the formation of increasing amounts of the anti-NPT/NPT complex in which FRET takes place. The assay system was found to display a high specificity and a low detection limit (0.14 ng mL -1 ) for NPT. A practical application of the FRET immunoassay system was demonstrated by its use in the detection of NPT in spiked human serum samples. The observations made in these efforts show that the homogeneous FRET immunoassay strategy, which requires a simple sample preparation procedure, serves as a powerful tool for the rapid and sensitive quantitative determination of NPT.
INTRODUCTION
Neopterin (NPT) is an early and valuable biomarker of cellular immune response. Raised NPT concentrations in body fluids could be detected in various pathologies, such as viral and bacterial infections, autoimmune, neurodegenerative, cardiovascular, and malignant disorders [1] . The normal blood NPT levels for healthy adults are not more than 9-10 nmol/l [2] . Otherwise, the levels above 10 nmol/l are regarded as elevated. Therefore, the determination of NPT in blood donor samples is an innovative tool in order to reduce the risk of infections via blood transfusion and for monitoring diseases which are associated with the activation of cell-mediated immunity [3] .
For the measurement of NPT levels in serum or biological samples, analytical tools like high-performance liquid chromatography (HPLC) [4, 5] , capillary electrophoresis [6] , fluoroimmunoassay (FIA) [7] , radioimmunoassay (RIA) [8, 9] , and enzyme-linked immunosorbent assay (ELISA) [10, 11] have been used. Although some of analytical techniques give sensitive and accurate result, they require the involvement of skilled personnel and expensive instrumentation. Furthermore, these methods often use of complex preparation steps that include labeling procedures, long incubation times and tedious washing. On the other hand, label-free homogenous fluorescence immunoassay methods for ligand detection, which do not require labeling of an antibody with fluorophore, are more effective from the perspective of both cost and time as well as not altering antibody function [12] [13] [14] .
Recently, we have developed label-free, non-competitive, FRET immunoassay for the detection of mycotoxins in the homogeneous solution [12, 14] . In these systems, fluorescence energy is transferred from Trp in the antibody to the target antigen and, as a result, the intrinsic fluorescence intensity of antibody or antigen is changed.
Here, we have devised this type of direct approach to construct a FRET immunoassay system for the detection of NPT, which has absorption spectrum that overlap with the emission spectra of Trp fluorophores in antibodies. We observed that fluorescence of antibodies is quenched when NPT is bound. In addition, the utility of the FRET immunoassay has been demonstrated by its application to the detection of NPT in the spiked human serum samples.
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EXPERIMENTAL SECTION
Reagents. Neopterin (NPT), biopterin (BPT), anti-mouse IgG antoibody (anti-mouse IgG), human serum, and sodium bicarbonate were purchased from Sigma-Aldrich Chemical Co. (Yongin, South Korea). Anti-NPT antibody (anti-NPT) was purchased from Selective Antibodies Ltd. (Newcastle, UK). Anti-interferon-gama antibody (anti-INF-) was purchased from BD Bioscience (California, USA). Anti-CRP antibody (anti-CRP) was purchased from Abcam Inc. (Cambridge, UK). All antibodies were desalted by using a Zeba TM Spin desalting column (100 K, Pierce Biotechnology, Inc.) before use. All other chemicals and organic solvents used were of reagent grade or better. Preparation of the FRET immunoassay system for NPT detection. The samples used for the NPT FRET immunoassay system were prepared by adding 1.5 μL 1 mg/mL anti-NPT stock solution, along with 147 μL of 10 mM NaHCO 3 buffer (pH 9.0) to fluorescence measurement cells. After the addition of 1.5 μL of various concentrations NPT solution, the solutions were incubated at room temperature for 20 min followed by fluorescent intensity measurements. Determination of the specificity of the FRET immunoassay system. In order to determine the specificity of the FRET immunoassay system, independent solutions containing NPT (2 and 20 ng mL -1 ) and either 30 μg mL -1 of anti-mouse IgG, 20 μg mL -1 of anti-IFN-, or 20 μg mL -1 of anti-CRP, and 10 μg mL -1 of anti-NPT were prepared and subjected to fluorescence measuremnts. In addition, solutions containing 10 μg mL -1 of anti-NPT and 2 or 20 ng mL -1 BPT were prepared and subjected to fluorescence analysis.
RESULTS AND DISCUSSION
As shown in Scheme, fluorescence from an antibody undergoes partially quenching when it is ligated to its corresponding FRET acceptor antigen NPT. Irradiation of antibodies at 280 nm promotes fluorescence emission with maxima at ca. 350 nm, due to the intrinsic fluorescence of Trp residues [12] [13] [14] . In contrast, NPT display maximum fluorescence excitation intensities at ca. 360 nm when they are monitored at 450 nm (Fig. 1A) [15] . Inspection of the spectra displayed in the Fig. 1B demonstrates that the fluorescence of antibodies at 350 nm is quenched when its corresponding antigens, NPT is present. We reasoned that this phenomenon could be used to design a highly sensitive detection system for target NPT.
Scheme. Illustration of the strategy employed to design the homogeneous FRET immunoassay system for NPT detection
Sensitivity and limit of detection (LOD) of the FRET immunoassay
In the NaHCO 3 buffer system (pH 8.8) condition, the sensitivity and limit of detection (LOD) of the immunoassay system were determined. Observations made in experiments exploring changes in fluorescence intensities promoted by the addition of different concentrations of NPT to buffered solutions of anti-NPT ( Fig. 2A) show that as the concentration of NPT increases the relative fluorescence intensity increases owing to an increase in the amount of the NPT/anti-NPT complex formed. The LOD, which is the lowest analyte concentration required to produce a signal greater than 3 times the standard deviation of the noise level (S/N=3), of this system was found to be ca. 0.14 ng mL -1 .
Specificity
Studies were carried out to probe the specificity of the FRET immunoassay system. For this purpose, anti-mouse IgG, anti-CRP, and anti-IFN- were employed as non-specific antibodies. Importantly, no significant changes in fluorescence intensity was observed to take place when the anti-mouse IgG, anti-CRP, and anti-IFN- were added to solutions containing 2 and 20 ng mL -1 of NPT (Fig. 2B ). In addition, the specificity issue was explored using NPT analogue, biopterin (BPT). The results show that no significant changes in fluorescence intensity is observed when BPT solutions are mixed with the anti-NPT at concentrations which match those used in the NPT assay (Fig. 2B) . These findings suggest that the FRET phenomenon is a consequence of specific interactions between NPT and anti-NPT. Importantly, the combined results show that the FRET immunoassay system displays a high degree of specificity for the targeted biomarker NPT. 
Human serum analysis
To demonstrate its utility for quantitative detection of NPT in real samples, the FRET immunoassay system was employed to detect NPT in spiked human serum samples. Human sera, spiked with specific concentrations of NPT (5 and 20 ng mL -1 ), were passed through Centricon centrifugal filter (50 K, Millipore). After mixing with 10 μg mL -1 of anti-NPT, the flow-through solutions were incubated at room temperature for 20 min. Comparisons with FRET intensity of NPT in buffer solution, showed that the percentages of NPT detected in the human serum are 93.6 and 113.2% for the respective 5 and 20 ng mL -1 samples (shown in Table 1 ). This observation demonstrates that the assay system displays a high level of detection accuracy. 113.2%
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In conclusion, we have developed a simple, rapid, label-free, non-competitive, and homogenous FRET immunoassay system for the sensitive and specific detection of the biomarker, NPT. The operational principle behind the system is that the intrinsic fluorescence of anti-NPT is quenched upon binding of the target antigen NPT. Furthermore, the FRET immunoassay system displays a high degree of specificity for NPT. Finally, we have demonstrated an application of the new assay procedure by using it to detect NPT in spiked human serum samples.
